From: Validity of a Cochrane Systematic Review and meta-analysis for determining the safety of vitamin E
Trial Period | Active n/Na | Control n/N | ATBC Weighting | Low risk Bias Subset RR | 95% CIs | P value | Figure |
---|---|---|---|---|---|---|---|
At the Margins Analysis (4 cell analysis) | |||||||
All Vit E | All non-Vit E | ||||||
April 1985–April 1993b | 1800/14564 | 1770/14569 | 21.5 | 1.01 | 0.98–1.05 | 0.34 | S4 |
April 1985–April 1996 | 2993/14564 | 3019/14569 | 33.8 | 1.01 | 0.98–1.03 | 0.70 | S5 |
April 1985–April 1999 | 4453/14564 | 4415/14569 | 46.2 | 1.01 | 0.99–1.04 | 0.37 | S6 |
April 1985–April 2001 | 5433/14564 | 5398/14569 | 53.7 | 1.01 | 0.99–1.03 | 0.40 | S7 |
April 1985–April 2011 | 10,182/14564 | 10,074/14569 | 81.7 | 1.01 | 1.00–1.03 | 0.11 | S8 |
Inside the Table Analysis (2 cell analysis) | |||||||
Vit E Alone | Placebo | ||||||
April 1985–April 1993a | 868/7286 | 851/7287 | 11.6 | 1.01 | 0.98–1.05 | 0.38 | S9 |
April 1985–April 1996 | 1434/7286 | 1449/7287 | 19.5 | 1.01 | 0.98–1.04 | 0.59 | S10 |
April 1985–April 1999 | 2167/7286 | 2117/7287 | 29.0 | 1.02 | 0.99–1.05 | 0.24 | S11 |
April 1985–April 2001 | 2671/7286 | 2605/7287 | 35.7 | 1.02 | 0.99–1.05 | 0.18 | S12 |
April 1985–April 2011 | 5065/7286 | 5022/7287 | 68.8 | 1.01 | 0.99–1.03 | 0.28 | S13 |
Bjelakovic (3 cell analysis) | |||||||
All Vit E | Placebo | ||||||
April 1985–April 1993a | 1800/14564 | 851/7287 | 15.0 | 1.02 | 0.99–1.06 | 0.19 | S14 |
April 1985–April 1996 | 2993/14564 | 1449/7287 | 24.7 | 1.02 | 0.99–1.05 | 0.20 | S15 |
April 1985–April 1999 | 4453/14564 | 2117/7287 | 35.4 | 1.03 | 1.00–1.06 | 0.04 | S16 |
April 1985–April 2001c | 5433/14564 | 2605/7287 | 42.6 | 1.03 | 1.00–1.05 | 0.04 | S1 |
April 1985–April 2011 | 10,182/14564 | 5022/7287 | 74.6 | 1.01 | 1.00–1.03 | 0.09 | S17 |